Terapia

Negli ultimi anni, con l'avvento dei farmaci orientati a target molecolari, sono emerse nuove stimolanti problematiche, che st

In the age of the World Wide Web, informed patients continue to surprise oncologists with detailed questions about popular tumor therapies. Although minimally invasive tumor therapies (MITT) have become daily clinical practice for palliative treatment of liver tumors, the acceptance of these palliative modalities still varies enormously. This book gives an up-to-date overview of the popular techniques and clinical results of MITT, with a clarification of the actual indications including the size, tumor entities, and clinical benefits. Moreover, the book focuses on the prospectives and limitations of imaging methods used for MITT.

"Regional Oncotherapies" is intended to give the practicing surgeon and oncologists or trainee an in-depth analysis of the technical aspects, their indications, contraindications, and complications of all interventional techniques procedures in oncotherapy.

The aim of this book is to provide an introduction to the principles of drug treatment for solid tumours in cancer medicine. Developments in the understanding of tumour biology, molecular biology and genetics - together with the greater understanding of the pharmacology and pharmacokinetics of drugs - have combined to open up the field of medical oncology to rapid advances in the treatment of cancers. The range of drugs that are available is wide and one of the primary aims in drug development is to increase the therapeutic window so that drug toxicity is minimised and tolerable. Drug development of oral formulations of anticancer drugs and the use of drugs that could be given in the day patient setting means that healthcare professionals such as general practitioners - who historically might not have been involved in the drug treatment of the cancer patient - are now going to need to have a greater understanding of the principles of use of anticancer drugs. This book is primarily aimed at this market.

Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development-those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can "reasonably predict" clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.

This is a comprehensive reference survey on the identification and development of promising cancer chemopreventive agents that will help stimulate further novel research and new approvable drugs. For each agent, the authors review the relevant mechanisms of action, the criteria for populations benefiting from intervention, the safety and pharmacodynamics, clinical study design emphasizing the use of precancers, and early associated cellular and molecular biomarkers of carcinogenesis. The pharmacologic and/or mechanistic classes discussed range from antimutagens, antiinflammatories, and the nuclear receptor superfamily, to signal transduction modulators, antioxidants, vitamins, and minerals. The overall focus is on molecular targets and mechanisms. A second volume, "Strategies in Chemoprevention", describes the exciting methodologies that will accelerate progress in this field and discusses the state of clinical development of chemoprevention in the various human cancer target organs.

Designed for quick reference, this handbook provides easily accessible information on the specific drugs and treatment regimens used in cancer chemotherapy. This updated Second Edition includes new drugs and combinations of drugs and reflects the increasing use of chemotherapy in combination with radiation and surgery. The first section presents site-specific cancer staging tables, treatment recommendations, and combination chemotherapy regimens and includes chapters on toxicity grading, dose modifications, and precautions. The second section alphabetically lists all current chemotherapeutic agents and provides essential information on each drug, including interactions, toxicity, indications, and dosing. The third section focuses on control of side effects. This edition is also available electronically for handheld computers. See PDA listing for details.

There have been very significant advances across many areas of the study, investigation and treatment of breast cancer. This publication surveys how scientific advances have influenced, improved and extended therapeutic options. The volume spans prevention, screening, genetics, and treatment of pre-invasive breast cancer, before focusing in depth on management of established breast cancer. This includes chapters on the various therapeutic options available and their role in treating breast cancer from the very earliest stage through to advanced and metastatic breast cancer. In addition, the text looks forward at the potential for emerging experimental strategies to become adopted into medical management in the future. The volume concludes with a chapter on palliative care. This wide-ranging account will be essential for breast cancer specialists, trainees in oncology and clinical research scientists.

The quest for therapeutic specificity is implicit in all branches of medicine. In cancer treatment, where the therapeutic modality is a cytotoxic agent such as radiotherapy or chemotherapy, such specificity is of paramount importance. The growing realisation that current therapeutic options are likely to yield no more than incremental improvements in outcome has fuelled the search for more active targeted approaches. This book discusses the more archetypal systemic targeted therapies, such as those employing monoclonal antibodies or liposomes, but also includes strategies, such as photodynamic therapy and boron neutron capture therapy, that rely on direct physical targeting of disease. The explosion in our understanding of the molecular biology of cancer in recent years has led to the identification of a number of new potential therapeutic targets. These factors, combined with the likelihood that yet more valuable information will be gleaned from the Human Genome Project, mean that inevitably, significant clinical activity in this arena is anticipated in the coming years with the very real prospect that gene therapy approaches may find an established role in the standard treatment of some of the common cancers. This book brings together the very latest research in this field from an international group of experts and will prove invaluable for molecular oncologists, cancer researchers and those involved with clinical trials as well as providing a reference for oncologists who are beginning to use some of these therapies in everyday clinical practice.

The revelation that aspirin and aspirin-like compounds have notableantineo- plastic properties has revolutionized cancer research. COX-2 Blockade in Cancer Prevention and Therapy chronicles the evidence and presents exciting new op- portunities for the use of cyclooxygenase-2 (COX-2) blockade in the prevention and treatment of cancer. The text is divided broadly into five areas. First, an historical overview documents the scientific discovery ofCOX-2 and the pharma- ceutical development of nonsteroidal anti-inflammatory drugs (NSAIDs) designed for selective COX-2 inhibition. The process by which essential poly- unsaturated fatty acids (PUF As) stimulate prostaglandin biosynthesis and cancer development, and its interruption by COX-2 inhibition, is elucidated. This is followed by a section on the epidemiology of NSAIDs and cancers of the colon and breast, and other anatomic sites. These chapters reflect significant cancer protection owing to the regular use of common NSAIDs such as aspirin and ibuprofen. A section on animal models of carcinogenesis presents comprehensive evidence that general NSAIDs inhibit a variety of malignant neoplasms in vivo, and highlights recent findings which show that COX-2 blocking agents produce striking chemopreventive effects against colon cancer and breast cancer as well as other malignancies. Genetic models are presented confirming the critical role of COX-2 in carcinogenesis. Section IV then discusses the molecular biology of COX -2 vis-a-vis the role of COX -2 and, to a lesser extent, COX -1, in modulating a number of important processes in molecular carcinogenesis such as mutagen- esis, cell division, angiogenesis, cell differentiation, and apoptosis.

In developing annual 20 the goal of the editors was to offer a timely critical review of the literature that has appeared in 2001 focusing mainly on novel therapeutic approaches in the areas of drugs and biologics.

In Tumor Targeting in Cancer Therapy, Dr. Michel Page and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand.